A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
B-cell Malignancy · Marginal Zone Lymphoma · Follicular Lymphoma · Non-Hodgkin Lymphoma · Waldenström Macroglobulinemia · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Mantle Cell Lymphoma · Diffuse Large B Cell Lymphoma · Richter Transformation
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 689 (planned)
- Started
- Sep 13, 2021
- Main results expected
- Mar 2027
- Fully finished
- Mar 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Number of Participants with Adverse Events (AEs)
Measured over: From the first dose of tacabrutideg until 30 days after the last dose of the study drug or before the initiation of a new anticancer therapy, whichever occurs first (Up to 47 weeks)
Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Tacabrutideg
Measured over: Approximately 28 days
Phase 1: Recommended dose(s) for Expansion (RDFE) of tacabrutideg
Measured over: Approximately 3 years
Phase 2: Overall response rate (ORR)
Measured over: approximately 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05006716 · record last updated 2026-10-05 · checked 2026-11-09 15:47 UTC